Patients with resected, early-stage non-small cell lung cancer (NSCLC) may benefit from adjuvant immunotherapy following adjuvant chemotherapy, according to new findings from a trial of atezolizumab. Presented at the European Society for Medical Oncology (ESMO) virtual Congress 2021, the results from the IMpower010 phase 3 RCT showed that atezolizumab extended disease-free survival in patients with stage II–IIIA ...
Adjuvant immunotherapy ‘the new standard of care’ in patients with resected, early-stage NSCLC
By Michael Woodhead
23 Sep 2021